Back to top
more

Ironwood Pharmaceuticals, Inc. (IRWD)

(Delayed Data from NSDQ)

$11.16 USD

11.16
1,600,728

+0.17 (1.55%)

Updated May 12, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 18% (206 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for IRWD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Ironwood Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 364 178 174 221 305
Receivables 122 117 81 82 65
Notes Receivable 0 0 0 0 0
Inventories 0 1 0 1 1
Other Current Assets 9 11 11 7 9
Total Current Assets 496 307 266 312 380
Net Property & Equipment 9 12 17 17 21
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 23 33 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 1 1 161 167
Deposits & Other Assets 14 32 48 116 142
Total Assets 559 403 332 606 710
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 1 5 18 16 18
Current Portion Long-Term Debt 0 0 48 0 0
Current Portion Capital Leases 0 0 0 4 6
Accrued Expenses 28 33 53 46 45
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 1 0 0 22
Total Current Liabilities 32 41 120 66 91
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 6 5 1
Convertible Debt 430 408 266 249 234
Long-Term Debt 0 0 101 147 132
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 14 25 36 128 185
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 497 496 528 596 643
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,529 1,479 1,395 1,319 1,258
Retained Earnings -1,466 -1,572 -1,591 -1,309 -1,192
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 63 -93 -196 10 67
Total Liabilities & Shareholder's Equity 559 403 332 606 710
Total Common Equity 63 -93 -196 10 67
Shares Outstanding 160.60 157.50 154.40 150.40 147.10
Book Value Per Share 0.39 -0.59 -1.27 0.07 0.45

Fiscal Year End for Ironwood Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 440 364 309 255 232
Receivables 87 122 113 105 91
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 11 9 11 14 10
Total Current Assets 538 496 433 374 334
Net Property & Equipment 9 9 9 11 12
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 24 23 23 23 23
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 13 14 10 18 18
Total Assets 599 559 492 444 404
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 1 1 2 3 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 20 28 27 20 21
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 1 1 1
Total Current Liabilities 24 32 33 27 28
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 436 430 425 419 413
Long-Term Debt 0 0 0 0 12
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 10 8 14 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 489 497 486 480 476
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,536 1,529 1,515 1,507 1,497
Retained Earnings -1,426 -1,466 -1,509 -1,544 -1,569
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 110 63 6 -37 -72
Total Liabilities & Shareholder's Equity 599 559 492 444 404
Total Common Equity 110 63 6 -37 -72
Shares Outstanding 160.90 160.60 160.00 159.90 159.30
Book Value Per Share 0.68 0.39 0.04 -0.23 -0.45